Review | Published:

Hyperinsulinemic hypoglycemia after gastric bypass surgery: what’s up and what’s down?

International Journal of Obesity volume 42, pages 286294 (2018) | Download Citation

Abstract

Obesity is a global public health problem and attempts to treat this condition using life style with and without pharmacological interventions have not been successful in majority of obese individuals. To date, the most effective treatment for obesity is weight loss surgery. One of the most widely used procedures to treat obesity worldwide, Roux-en-Y gastric bypass surgery (RYGB), has shown to induce diabetes remission in addition to significant and sustainable weight loss. As the number of this procedure performed over the last two decades increased, it has become clear that a subgroup of individuals develop postprandial hypoglycemia several years after surgery. This debilitating late complication of RYGB is often associated with loss of consciousness or seizures, and in severe cases, it is only partially responsive to diet modification or other available therapeutic options. The diagnosis is often a challenge resulting in delays in receiving care in the affected individuals. Although the underlying mechanisms are under current investigations, growing evidence suggest that a combination of exaggerated meal-derived nutrient appearance to systemic circulation and altered islet and gut hormone response after eating have a role in pathogenesis of this condition. The goal of this review is to highlight new perspectives regarding this life-threatening complication of RYGB. The etiology, diagnosis, recommendation on how to distinguish from classic dumping and current available treatment based on literature review will be discussed. In addition, physiologic changes after gastric bypass predisposing to hypoglycemia syndrome will be highlighted.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    WHO Obesity and overweight fact sheet 311-updated June 2016.

  2. 2.

    , , , . Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 2001; 74: 579–584.

  3. 3.

    , , , , , et al. Long-term weight loss maintenance in the United States. Int J Obes (Lond) 2010; 34: 1644–1654.

  4. 4.

    , , , , , et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365: 1597–1604.

  5. 5.

    , , , , , et al. Persistent metabolic adaptation 6 years after ‘The Biggest Loser’ competition. Obesity 2016; 24: 1612–1619.

  6. 6.

    , , , , , et al. Association of pharmacological treatments for obesity with weight loss and adverse events. JAMA 2016; 315: 2424–2434.

  7. 7.

    . History of obesity surgery. Surg Obes Relat Dis 2005; 1: 123–125.

  8. 8.

    , . Gastric obesity surgery combined with partial ileal bypass for hypercholesterolemia. Obes Surg 1997; 7: 313–316.

  9. 9.

    , , , , , et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248–256.

  10. 10.

    , , , , , et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ 2013; 347: f5934.

  11. 11.

    , , , , , et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003; 238: 467–484 discussion 84–85.

  12. 12.

    , , , , , et al. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005; 48: 2236–2240.

  13. 13.

    , , , , , . Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353: 249–254.

  14. 14.

    , , , . Nationwide cohort study of post-gastric bypass hypoglycaemia including 5040 patients undergoing surgery for obesity in 1986–2006 in Sweden. Diabetologia 2010; 53: 2307–2311.

  15. 15.

    , , , , , et al. Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet. Surg Obes Relat Dis 2008; 4: 492–499.

  16. 16.

    , , , , , et al. Risk of post-gastric bypass surgery hypoglycemia in nondiabetic individuals: a single center experience. Obesity 2016; 24: 1342–1348.

  17. 17.

    , . Adenoma of islet cells with hyperinsulinism: a review. Ann Surg 1935; 101: 1299–1335.

  18. 18.

    , , , . Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 1993; 42: 1791–1798.

  19. 19.

    , . The diagnosis of postprandial hypoglycemia. Diabetes 1981; 30: 996–999.

  20. 20.

    , , . Altered islet function and insulin clearance cause hyperinsulinemia in gastric bypass patients with symptoms of postprandial hypoglycemia. J Clin Endocrinol Metab 2014; 99: 2008–2017.

  21. 21.

    , , , , , et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab 2012; 303: E122–E131.

  22. 22.

    , , . Evidence from a single individual that increased plasma GLP-1 and GLP-1-stimulated insulin secretion after gastric bypass are independent of foregut exclusion. Diabetologia 2014; 57: 1495–1499.

  23. 23.

    , , , , , . Abnormal glucose tolerance testing following gastric bypass demonstrates reactive hypoglycemia. Surg Endosc 2011; 25: 1926–1932.

  24. 24.

    , , , , , . Hypoglycemia after Roux-En-Y gastric bypass: detection rates of continuous glucose monitoring (CGM) versus mixed meal test. Surg Obes Relat Dis 2015; 11: 564–569.

  25. 25.

    , , , . Dumping syndrome after esophageal, gastric or bariatric surgery: pathophysiology, diagnosis, and management. Obes Rev 2017; 18: 68–85.

  26. 26.

    , , . Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 2011; 60: 2308–2314.

  27. 27.

    . A clinical diagnostic index in the diagnosis of the dumping syndrome. Acta Med Scand 2009; 188: 479–486.

  28. 28.

    , , , . Oral glucose tolerance test compared with a mixed meal in the diagnosis of reactive hypoglycemia. A caveat on stimulation. Mayo Clin Proc 1983; 58: 491–496.

  29. 29.

    , , , , , et al. Comparison of oral glucose tolerance tests and mixed meals in patients with apparent idiopathic postabsorptive hypoglycemia: absence of hypoglycemia after meals. Diabetes 1981; 30: 465–470.

  30. 30.

    , , , , , et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg 2012; 22: 1084–1096.

  31. 31.

    , , , . Glycemic profile assessment using continuous glucose monitoring in patients with and without hypoglyemia after gastric bypass surgery. Diabetes 2012; 61 (Issue Supplement 1).

  32. 32.

    , , , , , et al. Insulinoma after bariatric surgery: diagnostic dilemma and therapeutic approaches. Obes Surg 2016; 26: 874–881.

  33. 33.

    , , , , , et al. Accurate preoperative localization of insulinomas avoids the need for blind resection and reoperation: analysis of a single institution experience with 17 surgically treated tumors over 19 years. J Gastrointest Surg 2009; 13: 1071–1077.

  34. 34.

    , , , , , et al. Glucagon-like peptide-1 (GLP-1) receptors are not overexpressed in pancreatic islets from patients with severe hyperinsulinaemic hypoglycaemia following gastric bypass. Diabetologia 53: 2641–2645.

  35. 35.

    , , . Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. Gastroenterology 2014; 146: 669–680.

  36. 36.

    , , , , , et al. Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes 2014; 63: 483–493.

  37. 37.

    , , , , , et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab 2007; 92: 4678–4685.

  38. 38.

    , , , , . Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia. Diabetologia 2017; 60: 531–540.

  39. 39.

    , , . Gastric bypass alters both glucose-dependent and glucose-independent regulation of islet hormone secretion. Obesity 2015; 23: 2046–2052.

  40. 40.

    , , , , , . Gastric bypass reduces symptoms and hormonal responses in hypoglycemia. Diabetes 2016; 65: 2667–2675.

  41. 41.

    , , . Insulin response to oral stimuli and glucose effectiveness increased in neuroglycopenia following gastric bypass. Obesity (Silver Spring) 2015; 23: 798–807.

  42. 42.

    , , , , , . Effect of carbohydrate restriction in patients with hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass. Obes Surg 2014; 24: 1850–1855.

  43. 43.

    , , , , , . Postprandial glucose and insulin responses to meals containing different carbohydrates in normal and diabetic subjects. N Engl J Med 1983; 309: 7–12.

  44. 44.

    , , . Post-gastric bypass hyperinsulinemic hypoglycemia: fructose is a carbohydrate which can be safely consumed. J Clin Endocrinol Metab 2015; 100: 3097–3102.

  45. 45.

    , , , , . Bedtime uncooked cornstarch supplement prevents nocturnal hypoglycaemia in intensively treated type 1 diabetes subjects. J Intern Med 1999; 245: 229–236.

  46. 46.

    , . Mini-special issue paper management of diabetic patients with hypoglycemic agents α-glucosidase inhibitors and their use in clinical practice. Arch Med Sci 2012; 5: 899–906.

  47. 47.

    , , , , , . Acarbose improves hypoglycaemia following gastric bypass surgery without increasing glucagon-like peptide 1 levels. Obes Surg 2012; 22: 582–586.

  48. 48.

    , , , , , et al. Scope and specificity of acarbose in slowing carbohydrate absorption in man. Diabetes 1981; 30: 951–954.

  49. 49.

    , , , , , et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 2005; 152: 757–767.

  50. 50.

    , , , , , et al. A pilot study of the effects of the somatostatin analog pasireotide in postoperative dumping syndrome. Neurogastroenterol Motil 2014; 26: 803–809.

  51. 51.

    , , , , , . Prolonged successful therapy for hyperinsulinaemic hypoglycaemia after gastric bypass: the pathophysiological role of GLP1 and its response to a somatostatin analogue. Eur J Endocrinol 2012; 166: 951–955.

  52. 52.

    , . Successful medical management of status post-Roux-en-Y-gastric-bypass hyperinsulinemic hypoglycemia. Obes Surg 2009; 19: 1333–1334.

  53. 53.

    , , , , , . Use of diazoxide in management of severe postprandial hypoglycemia in patient after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2010; 9: e18–e19.

  54. 54.

    , , , , , . Weight loss in obese men by caloric restriction and high-dose diazoxide–mediated insulin suppression. Diabetes, Obes Metab 2008; 10: 1195–1203.

  55. 55.

    , . Calcium antagonists and hormone release. I. Effects of verapamil on insulin release in normal subjects and patients with islet-cell tumor. Metabolism 1980; 29: 599–604.

  56. 56.

    , , , , , et al. Calcium antagonists and hormone release. VI. Effects of a calcium antagonist (verapamil) on the biphasic insulin release in vivo. Diabetes Res 1988; 8: 21–24.

  57. 57.

    , , , , . Effect of nifedipine on glucose potentiation of the acute insulin response to arginine in non-insulin-dependent diabetics. Eur J Clin Pharmacol 1991; 41: 411–415.

  58. 58.

    , , , . Oral verapamil does not affect glucose tolerance in non-diabetics. Br J Clin Pharmacol 1983; 15: 570–571.

  59. 59.

    , , , , , . Influence of oral verapamil on glucoregulatory hormones in Man*. J Clin Endocrinol Metab 1985; 60: 536–541.

  60. 60.

    , , , , . Post-prandial hypoglycemia after bariatric surgery: pharmacological treatment with verapamil and acarbose. Obes Surg 2008; 18: 1618–1621.

  61. 61.

    , , , , . XOMA 358, a novel treatment for hyperinsulinemic hypoglycemia: safety and clinical pharmacology from the first in human trial. Endocrine Rev 2015; 36 (Issue 2 Supplement).

  62. 62.

    , , , , , et al. Single administration of Xoma 358, an insulin receptor attentuator improves post-meal and nighttime hypoglycemia profiles in post gastric bypass hypoglycemia (PGBH) patients. Endocrine Rev 2017; Vol 38 (Issue 2 Supplement).

  63. 63.

    , , , , , et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010; 33: 1282–1287.

  64. 64.

    . Automatec event-based system for the prevention of post-bariatric hypoglycemia using a mini-dose of a stable glucagon formulation. Endocrine Rev 2017; 38 (Issue 2 Supplement).

  65. 65.

    . Subcutaneous exendin 9-39 effectively treats post-bariatric hypoglycemia. Diabetes 2016; 65 (Issue Supplement 1).

  66. 66.

    . Postprandial hyperinsulinemic hypoglycemia after gastric bypass surgical treatment. Surg Obes Relat Dis 2014; 10: 1220–1225.

  67. 67.

    , , , , , et al. Total pancreatectomy for the management of refractory post-gastric bypass hypoglycemia. Dig Dis Sci 2015; 60: 1505–1509.

  68. 68.

    , , , . Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery. J Clin Endocrinol Metab 2010; 95: 1851–1855.

  69. 69.

    , , , , , et al. Severe recurrent hypoglycemia after gastric bypass surgery. Obes Surg 2008; 18: 981–988.

  70. 70.

    , , , , , et al. Outcomes and quality of life after partial pancreatectomy for noninsulinoma pancreatogenous hypoglycemia from diffuse islet cell disease. Surgery 2010; 148: 1237–1246.

Download references

Acknowledgements

Marzieh Salehi is a scientific consultant with Eiger Pharm Co.; however, this has no effect on the materials presented. This work was supported by the National Institutes of Health grants: DK083554-05 (MS) and DK105379 (MS).

Author information

Affiliations

  1. Division of Endocrinology, Department of Medicine, Diabetes and Metabolism, University of Cincinnati College of Medicine, Cincinnati, OH, USA

    • A Yaqub
    •  & E P Smith
  2. Division of Endocrinology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    • M Salehi

Authors

  1. Search for A Yaqub in:

  2. Search for E P Smith in:

  3. Search for M Salehi in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to A Yaqub.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/ijo.2017.257